GlassScriptPhysician profile
Roberto Jesus Bernardo
NPI 1063853109
$97,150.15
in general payments reported to CMS, 2019-2025
20 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $38.11 · 2021: $819 · 2022: $10K · 2023: $7,011 · 2024: $31K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Travel and Lodging: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,011 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,096.25 |
| Travel and Lodging | $25,165.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,520.00 |
| Food and Beverage | $5,011.45 |
| Education | $167.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48,584.46 | 2022-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $28,832.61 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $18,334.24 | 2019-2025 | Remodulin, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $268.54 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $193.91 | 2019 | |
| Glaxosmithkline, LLC. | $187.42 | 2019 | |
| Allergan, INC. | $170.35 | 2019 | |
| Gilead Sciences, INC. | $131.33 | 2019 | |
| Mentor Worldwide LLC | $114.35 | 2021 | |
| Sandoz INC. | $67.83 | 2023-2024 | Treprostinil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.22 | 2019 | |
| Ekos Corporation | $37.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $33.92 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.85 | 2019 | |
| Novo Nordisk INC | $21.72 | 2023 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $19.97 | 2019 | |
| Chiesi USA, INC. | $19.35 | 2019 | |
| Edwards Lifesciences Corporation | $18.22 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.72 | 2019 | |
| Insmed, INC. | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Bernardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.